BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND KMT2A, TRX1, 4297, MLL, ENSG00000118058, MLL/GAS7, HTRX1, HRX, ALL-1, MLL1A, CXXC7 AND Treatment
15 results:

  • 1. [Clinical analysis of 12 cases of ovarian yolk sac tumor].
    Liu J; Chu HJ; Shan YP; Song WJ; Chen AP
    Zhonghua Fu Chan Ke Za Zhi; 2024 Mar; 59(3):210-214. PubMed ID: 38544450
    [No Abstract]    [Full Text] [Related]  

  • 2. Therapy-related acute myeloid leukemia with
    Yang X; Liu Q; Zhang R; Yang X; Wang L; Zhang Z; Li Y; Lin L
    Indian J Pathol Microbiol; 2023; 66(4):865-867. PubMed ID: 38084551
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
    Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
    BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Menin‑mll inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells.
    Kato I; Kasukabe T; Kumakura S
    Int J Oncol; 2020 Oct; 57(4):1057-1071. PubMed ID: 32945449
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
    Fritz C; Portwood SM; Przespolewski A; Wang ES
    Blood Rev; 2021 Jan; 45():100696. PubMed ID: 32482307
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The Anti-Proliferative Effect of Flavonoid Nanoparticles on the Human ovarian cancer Cell Line SK0V3.
    Zhang C; Li X; Jin S; Zhang H; Wang R; Pei L; Zheng J
    J Nanosci Nanotechnol; 2020 Oct; 20(10):6040-6046. PubMed ID: 32384950
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
    Sarno F; Nebbioso A; Altucci L
    Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [
    Guo T; Dong X; Shi G
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 49(4):551-555. PubMed ID: 30378308
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy.
    Chen J; Solomides C; Simpkins F; Simpkins H
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):369-380. PubMed ID: 28120035
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.
    Foster JM; Sleightholm R; Smith L; Ceelen W; Deraco M; Yildirim Y; Levine E; Muñoz-Casares C; Glehen O; Patel A; Esquivel J
    J Surg Oncol; 2016 Dec; 114(7):779-784. PubMed ID: 27792292
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (trx1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
    Pontikakis S; Papadaki C; Tzardi M; Trypaki M; Sfakianaki M; Koinis F; Lagoudaki E; Giannikaki L; Kalykaki A; Kontopodis E; Saridaki Z; Malamos N; Georgoulias V; Souglakos J
    Pharmacogenomics J; 2017 Dec; 17(6):506-514. PubMed ID: 27779244
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Novel insights into the synergistic interaction of a thioredoxin reductase inhibitor and TRAIL: the activation of the ASK1-ERK-Sp1 pathway.
    Lin T; Chen Y; Ding Z; Luo G; Liu J; Shen J
    PLoS One; 2013; 8(5):e63966. PubMed ID: 23696862
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Altered expression of the septin gene, SEPT9, in ovarian neoplasia.
    Burrows JF; Chanduloy S; McIlhatton MA; Nagar H; Yeates K; Donaghy P; Price J; Godwin AK; Johnston PG; Russell SE
    J Pathol; 2003 Dec; 201(4):581-8. PubMed ID: 14648661
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Therapy related leukemias: susceptibility, prevention and treatment.
    Leone G; Voso MT; Sica S; Morosetti R; Pagano L
    Leuk Lymphoma; 2001 Apr; 41(3-4):255-76. PubMed ID: 11378539
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.